SUPERNUS PHARMACEUTICALS, INC. SUPERNUS PHARMACEUTICALS, INC. STRONGLY ENCOURAGES YOU TO SEEK THE ADVICE OF YOUR OWN LEGAL AND FINANCIAL ADVISORS WITH RESPECT TO YOUR AWARD AND ITS TAX CONSEQUENCES. FORM OF NON-STATUTORY TIME- BASED STOCK OPTION AGREEMENTTime-Based Stock Option Agreement • August 6th, 2021 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This agreement (the “Agreement”) evidences a stock option granted by Supernus Pharmaceuticals, Inc. (the “Company”) to the undersigned (the “Optionee”), pursuant to and subject to the terms of the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the “Plan”), which is incorporated herein by reference.
SUPERNUS PHARMACEUTICALS, INC. PERFORMANCE SHARE UNIT AWARD AGREEMENTPerformance Share Unit Award Agreement • August 6th, 2021 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Performance Share Unit Award Agreement (the “Agreement”) is made and entered into as of , (the “Grant Date”). This Agreement evidences a performance share unit award granted by Supernus Pharmaceuticals, Inc. (the “Company”) to the undersigned (“Participant”) pursuant to and subject to the terms of the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the “Plan”), which is incorporated herein by reference. Capitalized terms not explicitly defined in this Agreement shall have the meaning set forth in the Plan.
SUPERNUS PHARMACEUTICALS, INC. SUPERNUS PHARMACEUTICALS, INC. STRONGLY ENCOURAGES YOU TO SEEK THE ADVICE OF YOUR OWN LEGAL AND FINANCIAL ADVISORS WITH RESPECT TO YOUR AWARD AND ITS TAX CONSEQUENCES. FORM OF TIME-BASED INCENTIVE STOCK OPTION AGREEMENTBased Incentive Stock Option Agreement • August 6th, 2021 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This agreement (the “Agreement”) evidences a stock option granted by Supernus Pharmaceuticals. Inc. (the “Company”) to the undersigned (the “Optionee”), an employee of the Company or one of its subsidiaries, pursuant to and subject to the terms of the Supernus Pharmaceuticals. Inc. 2021 Equity Incentive Plan (the “Plan”), which is incorporated herein by reference.
SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENTRestricted Stock Unit Award Agreement • August 6th, 2021 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Restricted Stock Unit Award Agreement (the “Agreement”) is made and entered into as of , (the “Grant Date”). This Agreement evidences a restricted stock unit award granted by Supernus Pharmaceuticals, Inc. (the “Company”) to the undersigned (“Participant”) pursuant to and subject to the terms of the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the “Plan”), which is incorporated herein by reference. Capitalized terms not explicitly defined in this Agreement shall have the meaning set forth in the Plan.
CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED API SUPPLY AGREEMENTApi Supply Agreement • August 6th, 2021 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This API Supply Agreement (“Agreement”) is made as of July 13, 2021 (the “Effective Date”), by and between Supernus Pharmaceuticals, Inc., a Delaware Corporation, with a place of business at 9715 Key West Avenue, Rockville Maryland, USA (“Supernus”) and Bachem Americas, Inc., a California Corporation, with a place of business at 3132 Kashiwa Street, Torrance, CA 90505, USA, and its Affiliates (“Bachem”). Supernus and Bachem may be referred to individually as a “Party” or collectively as the “Parties.”
COMMERCIAL SUPPLY AGREEMENT (Viloxazine)Supply Agreement • August 6th, 2021 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Commercial Supply Agreement is made as of this 12th day of May, 2021 (the “Effective Date”), by and between Supernus Pharmaceuticals, Inc., a Delaware corporation, with a place of business at 9715 Key West Avenue, Rockville, MD 20850 (“Supernus”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, NJ 08873 (“Catalent”).
